Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclizumab High Yield Process vs Avonex in Relapsing-Remitting Multiple Sclerosis
DRKS00000438Phase 3Active, not recruiting
- Sponsor
- Biogen
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 28
01
Overview
A Phase 3 trial of daclizumab, interferon beta-1a in multiple sclerosis (MS), sponsored by Biogen. Started Nov 2010; status: active, not recruiting.
02
Drugs
daclizumabinterferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on DRKS00000438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00000438.